卵巢固定术后年轻宫颈癌患者卵巢剂量保护:三种放疗技术的剂量学与放射生物学比较
IMPT较光子技术显著降低卵巢平均剂量约95%,并改善靶区均匀性和多数OAR剂量参数;TOMO在高剂量OAR保护上有竞争力,VMAT束流时间最短。
要点
- IMPT卵巢平均剂量较光子技术降低约95%(0.11-0.35 Gy vs 4.44-5.24 Gy)。
- IMPT和TOMO对直肠、膀胱、小肠的高剂量保护优于VMAT。
- VMAT束流时间最短(2.20±0.05 min),TOMO为8.18±0.99 min。
核心结论
- IMPT在卵巢固定术后卵巢剂量保护中实现最低卵巢照射和最有利的总体剂量学表现。
- TOMO对多个盆腔OAR高剂量终点提供有竞争力的保护,VMAT提供最短光子束流时间。
- 上述优势为剂量学和模型估计优势,并非卵巢内分泌功能改善或临床毒性降低的直接证据。
研究设计与样本
- 为每例患者设计IMPT、TOMO和VMAT三种计划,统一处方45 Gy/25次。
- IMPT计划纳入稳健优化,考虑摆位不确定度5 mm和射程不确定度3.5%。
主要发现
- 三种技术均达到临床可接受的靶区覆盖,IMPT剂量均匀性最优。
- IMPT卵巢平均剂量较光子技术降低约95%(0.11-0.35 Gy vs 4.44-5.24 Gy)。
- IMPT和TOMO对直肠、膀胱和小肠的平均剂量均显著低于VMAT。
- IMPT较两种光子技术降低小肠平均剂量、膀胱平均剂量和正常组织积分剂量。
- 基于模型的NTCP分析显示IMPT对小肠、直肠和膀胱的估计并发症概率低于TOMO和VMAT。
关键数值与推荐
- 处方剂量为45 Gy分25次。
- IMPT稳健优化参数:摆位不确定度5 mm,射程不确定度3.5%。
- 卵巢平均剂量:IMPT 0.11-0.35 Gy,光子技术4.44-5.24 Gy。
- 束流时间:VMAT 2.20±0.05 min,TOMO 8.18±0.99 min。
临床怎么用
- 在资源可及时,IMPT可作为卵巢固定术后年轻宫颈癌患者卵巢剂量保护的最有利剂量学选择。
- VMAT和TOMO仍为合理备选,取决于临床优先事项和资源可及性。
- 解读本研究结果时应限定为剂量学和模型估计优势,不能直接外推为卵巢功能或临床毒性获益。
局限性
- 结论基于剂量学参数和模型估计,非卵巢内分泌功能或临床毒性的直接证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To systematically compare the dosimetric performance and model-based radiobiological estimates of intensity-modulated proton therapy (IMPT), helical tomotherapy (TOMO), and volumetric modulated arc therapy (VMAT) for ovarian dose sparing in young cervical cancer patients after oophoropexy. METHODS: Ten premenopausal cervical cancer patients who received postoperative pelvic radiotherapy following bilateral ovarian transposition were retrospectively enrolled. Three treatment plans (IMPT, TOMO, and VMAT) were designed for each patient with a uniform prescription of 45 Gy in 25 fractions. IMPT plans incorporated robust optimization accounting for setup uncertainty (5 mm) and range uncertainty (3.5%). Dosimetric parameters evaluated included target coverage ([Formula: see text]), homogeneity index (HI), ovarian mean dose ([Formula: see text]) and maximum dose ([Formula: see text]), and dose-volume metrics for organs at risk (OARs: rectum, bladder, small intestine, sigmoid, femoral heads). Radiobiological analyses included equivalent uniform dose (EUD), normal tissue complication probability (NTCP), and excess absolute risk (EAR) estimation for secondary malignancies using Schneider's mechanistic model. RESULTS: All three techniques achieved clinically acceptable target coverage. IMPT showed superior dose homogeneity and the most favorable planned ovarian dose-sparing profile, reducing ovarian [Formula: see text] by approximately 95% compared with photon-based techniques (0.11-0.35 Gy vs. 4.44-5.24 Gy, [Formula: see text]) and substantially lowering low-dose exposure ([Formula: see text] cc vs. 2.86-7.68 cc, [Formula: see text]). Both IMPT and TOMO achieved significantly lower [Formula: see text] to the rectum, bladder, and small intestine than VMAT ([Formula: see text]). IMPT also reduced small intestine [Formula: see text], mean bladder dose, and integral dose to normal tissue compared with both photon techniques ([Formula: see text]). Model-based NTCP analysis showed that IMPT yielded lower estimated complication probabilities for the small intestine, rectum, and bladder compared with TOMO and VMAT ([Formula: see text]), while femoral head estimates were comparable between IMPT and VMAT and lower than TOMO. EAR modeling suggested organ-specific and endpoint-dependent differences across pelvic OARs. VMAT had the shortest beam-on time (2.20 ± 0.05 min vs. TOMO 8.18 ± 0.99 min, [Formula: see text]). CONCLUSION: IMPT achieved the lowest ovarian radiation exposure and the most favorable overall dosimetric profile for ovarian dose sparing after ovarian transposition. TOMO provided competitive sparing for several high-dose pelvic OAR endpoints, whereas VMAT offered the shortest photon beam-on time. Overall, IMPT appears to be the most favorable dosimetric option for ovarian dose sparing when available, while VMAT and TOMO remain reasonable alternatives depending on clinical priorities and resource availability. These findings should be interpreted as dosimetric and model-based advantages rather than direct evidence of improved ovarian endocrine function or reduced clinical toxicity.
引用
- Xu M, Kang K, Zhao M, et al. Optimizing ovarian dose sparing for young cervical cancer patients after oophoropexy: a dosimetric and radiobiological comparison of three radiotherapy techniques (IMPT, TOMO, and VMAT). Radiat Oncol. 2026. PMID: 42243980. doi:10.1186/s13014-026-02862-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。